Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Adv Hematol Oncol. 2008 Feb;6(2):113-7.

Response in acute myeloid leukemia.

Author information

  • 1Division of Hematology, University of Washington Medical Center, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA 98109, USA. eestey@u.washington.edu

Abstract

For many years, response to induction therapy in acute myeloid leukemia was classified as "complete response" (CR) or "no CR." The emphasis on CR reflected the proven ability of CR to extend survival, the outcome of primary interest to patients. Beginning with the adoption of complete response with incomplete platelet recovery (CRp), recent years have seen the acceptance of responses less than CR as beneficial. Although these responses denote that a drug is active, relatively little attention has been paid to the effect of such responses on survival. This article explores the effect of such responses on survival.

PMID:
18347562
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk